Translate
Montreal, Quebec--(Newsfile Corp. - September 13, 2013) - A new technology announced by ProScanRxPharma Inc., Grafoid Inc. and Calevia Inc. can selectively search and destroy cancerous prostate cells and destroy them with a flash of red light combining biotechnology and advanced graphene technologies to provide ground-breaking new medical technology.
Reaching this level of innovation requires massive mastery of several fields of science, an effort with massive commercial applications. This is about finding the Holy Grail of cancer therapy: destroying cancer cells without difficult surgery that may or may not eliminate all the cancerous cells, or death defying chemotherapy. For many years now, researchers have been looking at ways to use graphene in cancer therapy by providing a focused way to eliminate cancer cells.
The new technology is rooted in a rudimentary principle that was discovered 100,000 years ago with the discovery of fire: fire burns — and further experimented by every toddler ever since.
Next it is draws on immunology, perhaps one of most misunderstood facet of medicine, by using antibodies that are specific to cancer cells. These antibodies bind to the walls of cancer cells but are rejected by healthy cells. Antibodies are the business end of the immune system that binds to microbes and foreign substances. In carcinogenesis the immune system is unable to produce them to destroy cancer cells. But what if we could arm antibodies with heat guns? Living cells are sensitive to high temperature — fire burns.
The researchers then used the antibodies to coat minuscule amounts of graphene, a single layer of carbon atoms, thus forming a bioconjugate or a biological computer chip. These graphene chips were fabricated for their ability to bind to the non-business end of the antibodies so that when they encounter cancer cells they can bind to their cell walls. This required finding a way to detoxify graphene, a unique process that was developed by Grafoid — graphene oxide is normally toxic to living cells.
This is when things get nasty for cancer cells: when graphene is exposed to near infrared wavelength, it turns it instantly turns it into heat. Near infrared is harmless red light and can’t be felt normally: TV remotes use near infrared waves. Near infrared can also penetrate tissues, hence it can reach tumours that are coated with the antibody-graphene bioconjugate. Again, we know that fire burns. In this case it only burns the cancerous cells.
According to Calevia’s co-founder Dr. Claude Vezeau who serves as President and CEO, further research is needed to calibrate the heat exposure to optimize the tumour removal treatment. In parallel, further research will also add therapies for example breast, kidney, bladder, and bladder cancers. So far these findings have been demonstrated on animal trials. Clinical trials on human subjects are planned within a 2-year horizon.
If these findings can be proven to cure cancer in humans, Calevia might offer us as much a quantum leap in medicine as when Sir Alexander Fleming and co-workers developed the antibiotic substance penicillin from the fungus Penicillium notatum in 1928. Fleming took medicine to a completely new level and triggered the pharmaceutical industry as we know it today.
About Grafoid Inc.
Grafoid Inc. is a privately held Canadian corporation investing in graphene applications and economically scalable production processes for MesoGraf™ – the global standard for graphene – and MesoGraf™Xide its trade mark graphene oxide produced from raw, unprocessed graphite ore. Focus Graphite Inc. (TSX VENTURE: FMS; OTCQX: FCSMF; FRANKFURT: FKC) holds a principal interest in Grafoid on behalf of its shareholders.
About ProScanRxPharma Inc.
ProScanRxPharma Inc. is an experienced developer of targeted monoclonal antibodies. ProScan is dedicated to the development of innovative solutions to improve and simplify the clinical management of patients suffering from prostate cancer. It applies modern technologies to develop new molecular tools to provide clinicians and their cancer patients with efficient diagnostic and treatment alternatives. ProScan’s products are expected to bring a new wave of solutions to clinicians and patients for the safer and more efficient detection and control of prostate cancer.
Forward Looking Statements – Disclaimer
This news release may contain forward looking statements, being statements which are not historical facts, and discussions of future plans and objectives. There can be no assurance that such statements will prove accurate. Such statements are necessarily based upon a number of estimates and assumptions that are subject to numerous risks and uncertainties that could cause actual results and future events to differ materially from those anticipated or projected.
InvestorIntel
Toll-free in North America: 1-866-544-9622
E-mail: Sue@InvestorIntel.com
www.InvestorIntel.com